---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-26-002932"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:47:09.836328+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital

## Summary
- Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.
- Sales occur under effective shelf registration statement (Form S-3, File No. 333-273610) from August 2023.
- Company controls timing, price, and volume; agent uses commercially reasonable efforts with no minimum commitment.
- Common stock trades on Nasdaq under ALZN; shares sold will be freely tradable.

## SEC filing metadata
- accession: 0001214659-26-002932
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/d362618k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-26-002932
- JSON: https://secwatch.observer/filing/0001214659-26-002932.json
- Plain text: https://secwatch.observer/filing/0001214659-26-002932.txt

## Key facts
- Material Agreements
  Alzamend Neuro, Inc. entered into At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC valued at up to $3.0 million (effective 2026-03-06).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Ascendiant Capital Markets, LLC
  - Value: up to $3.0 million
  - Effective: 2026-03-06
  source text: On March 6, 2026, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to $3.0 million (the “ Shares ”) from time to time, through an “at the market offering”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465926002932/0001214659-26-002932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.